齐鲁晚报·齐鲁壹点 记者 张洁清 1月6日，国家药监局发布2025年第47号通告，经广东省药品检验所检验，标示为江苏万邦生化医药集团有限责任公司生产的辅酶Q10注射液不符合规定。 根据公告显示，不符合规定项目涉及性状、不溶性微粒、可见异物、含量测定。对上述不符合规定药品，药品监督管理部门已责令企业对涉事药品采取暂 停销售使用、召回等风险控制措施，深入调查不符合规定原因并完成整改。省级药监部门将依据《中华人民共和国药品管理法》对企业涉嫌违法行为立案 调查，查处结果将按规定公开。 天眼查显示，江苏万邦生化医药集团有限责任公司是上海复星医药（600196）产业发展有限公司全资子公司，后者则是上海复星医药（集团）股份有限公 司（复星医药 600196.SH）全资子公司。上海复星医药（集团）股份有限公司成立于1994年，是一家创新驱动的全球化医药健康产业集团，直接运营的业 务包括制药、医疗器械与医学诊断、医疗健康服务，并通过联营公司国药控股覆盖到医药商业领域。 根据官网显示，2024年，江苏万邦生化医药集团有限责任公司更名为复星万邦（江苏）医药集团有限公司，是一家集研发创新、生产制造与市场推广于一 体的集团化企业。公司 ...

Core Viewpoint - The Medical Health Index (980016) closed at 6354.84 points, up 0.88%, with a trading volume of 29.705 billion yuan and a turnover rate of 1.0% on January 6 [1] Group 1: Index Performance - On the same day, 38 of the index's constituent stocks rose, with BGI Genomics leading with a 6.95% increase, while 11 stocks fell, with Zai Lab leading the decline at 3.72% [1] - The top ten constituent stocks of the Medical Health Index are detailed, with WuXi AppTec holding the highest weight at 10.23% and a latest price of 96.25 yuan, showing a 1.78% increase [1] Group 2: Market Capitalization - The total market capitalization of WuXi AppTec is approximately 287.187 billion yuan, while the highest market cap among the top ten is held by Hengrui Medicine at 418.542 billion yuan [1] - The market capitalization of the top ten stocks ranges from 489 million yuan for Kelun Pharmaceutical to 418.542 billion yuan for Hengrui Medicine [1] Group 3: Capital Flow - The net outflow of main funds from the constituent stocks totaled 471 million yuan, while retail investors saw a net inflow of 200 million yuan [1] - Detailed capital flow shows that WuXi AppTec had a net inflow of 180 million yuan from main funds, while Yeye Eye Care experienced a net outflow of 157 million yuan from retail investors [2]

Overview - The company Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has participated in the establishment of a private equity investment fund named "China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership)" [2] Group 1 - On October 28, 2025, the company signed a partnership agreement with 11 other investors to jointly establish the fund [2] - The fund has completed its registration with the Asset Management Association of China [3] - The fund is managed by Shenzhen China Resources Capital Equity Investment Co., Ltd. and is custodied by China Merchants Bank Co., Ltd. [3]

格隆汇1月5日丨复星医药(02196.HK)公告，2025年10月28日，上海复星医药(集团)股份有限公司(以下简 称"本公司")控股子公司上海复星医药产业发展有限公司与其他11方投资人签订《华润(成都)医药产业股 权投资基金合伙企业(有限合伙)有限合伙协议》，以共同出资设立华润(成都)医药产业股权投资基金合 伙企业(有限合伙)。近日，公司收到通知，该基金已于中国证券投资基金业协会完成备案。 ...

格隆汇1月5日丨 复星医药(02196.HK)公告，2025年10月28日，上海复星医药(集团)股份有限公司(以下 简称"本公司")控股子公司上海复星医药产业发展有限公司与其他11方投资人签订《华润(成都)医药产业 股权投资基金合伙企业(有限合伙)有限合伙协议》，以共同出资设立华润(成都)医药产业股权投资基金 合伙企业(有限合伙)。近日，公司收到通知，该基金已于中国证券投资基金业协会完成备案。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 參與認購之投資基金完成私募投資基金備案的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2026 年1 月5 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士 ...

证券代码：600196 股票简称：复星医药 编号：临 2026-001 以上详情请见本公司2025年10月29日于《中国证券报》《上海证券报》《证 券时报》和上海证券交易所网站（https://www.sse.com.cn）发布的相关公告。 上海复星医药（集团）股份有限公司 关于参与认购之投资基金完成私募投资基金备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 2025年10月28日，上海复星医药（集团）股份有限公司（以下简称"本公司"） 控股子公司上海复星医药产业发展有限公司与其他11方投资人签订《华润（成都） 医药产业股权投资基金合伙企业（有限合伙）有限合伙协议》，以共同出资设立 华润（成都）医药产业股权投资基金合伙企业（有限合伙）。 二、进展情况 近日，本公司收到通知，该基金已于中国证券投资基金业协会完成备案，备 案信息如下： 基金名称：华润（成都）医药产业股权投资基金合伙企业（有限合伙） 管理人名称：深圳市华润资本股权投资有限公司 托管人名称：招商银行股份有限公司 备案编码：SBLL28 特此公告。 ...

Core Insights - Fosun Pharma's stock price increased by 2.00% on January 5, reaching 27.02 CNY per share, with a total market capitalization of 721.55 billion CNY [1] - The company reported a net inflow of main funds amounting to 16.98 million CNY, with significant buying activity from large orders [1] - For the first nine months of 2025, Fosun Pharma achieved a revenue of 29.393 billion CNY, a year-on-year decrease of 4.91%, while net profit attributable to shareholders increased by 25.50% to 2.523 billion CNY [2] Company Overview - Fosun Pharma, established on May 31, 1995, and listed on August 7, 1998, is headquartered in Shanghai, focusing on pharmaceutical manufacturing and R&D, with a diverse business portfolio including medical devices, diagnostics, and retail [1] - The company's revenue composition includes 45.68% from anti-tumor and immune regulation products, 17.53% from anti-infection products, and 13.83% from metabolic and digestive system products [1] Shareholder and Dividend Information - Fosun Pharma has distributed a total of 12.593 billion CNY in dividends since its A-share listing, with 2.691 billion CNY distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 1.97% to 225,500, with no change in the average circulating shares per person [2][3]

Summary of Key Points Core Viewpoint - The report highlights the target price increases for several listed companies from December 29 to January 4, indicating strong bullish sentiment from brokers towards specific sectors, particularly semiconductor, pharmaceutical, and non-alcoholic beverage industries. Group 1: Target Price Increases - The companies with the highest target price increases include: - Lian Microelectronics (立昂微) with a target price increase of 121.14% to 77.00 CNY [1][2] - Fosun Pharma (复星医药) with a target price increase of 73.65% to 46.00 CNY [1][2] - Yanjing Beer (燕京啤酒) with a target price increase of 58.06% to 17.75 CNY [1][2] Group 2: Broker Recommendations - A total of 147 listed companies received broker recommendations during the same period, with notable mentions: - Guiguan Electric (桂冠电力) received recommendations from 3 brokers [3][4] - Haier Home (海澜之家) and Three Gorges Tourism (三峡旅游) each received recommendations from 2 brokers [3][4] Group 3: Rating Adjustments - Two companies had their ratings upgraded: - SF Express (顺丰控股) was upgraded from "Hold" to "Strong Buy" by China Merchants Securities [5] - Ruisheng Intelligent (瑞晟智能) was upgraded from "Hold" to "Buy" by Northeast Securities [5] Group 4: First-Time Coverage - During the same period, 54 instances of first-time coverage were reported, with key companies including: - Guohuo Airlines (国货航) receiving an "Accumulate" rating from Zheshang Securities [6] - Jing Shan Light Machinery (京山轻机) also received an "Accumulate" rating from Guotai Junan Securities [6]

以下文章来源于无冕财经 ，作者无冕财经团队 无冕财经 . 奉守"专业主义，内容为王"，为优质的商业阅读而生。多次获评"年度财经自媒体"，入选胡润百富"广 州最值得投资的企业"榜单50强，广州市新阶联自媒体分会副会长单位，入驻全网20多个平台，覆盖 1000万+商务人群，中国财经新媒体的中坚力量之一。 "神药"还不确定能重新上市。 作者：杨一轩 编辑：陈涧 千亿"复星系"的一笔收购，引来一片质疑之声。 12月23日晚间，郭广昌控股的复星医药（600196.SH），发出上万字公告，详细回复上交所 对于其收购绿谷医药的问询。 来源：无冕财经 ▲ 绿谷医药针对上交所问询进行回复。 在此前一周，复星医药宣布拟耗资14.12亿元，控股收购绿谷医药，市场哗然。复星医药的股 价应声下滑，近几日跌多涨少。 绿谷医药的全部价值，系于阿尔茨海默病药品甘露特钠胶囊（俗称"九期一"），但因为注册证 到期，该药品已经停止生产。绿谷医药也陷入亏损，净资产仅为约1000万。 复星医药买下的这家公司，资产价值不足收购款的百分之一，更何况，九期一虽贵为"神药"， 但学界质疑声不断。 凡此种种，让这笔收购被放置在聚光灯下，连监管也出面要求说明情况 ...